Dr Desai on Notable Ongoing Studies in Myeloproliferative Neoplasms

“I’m interested to see [findings with] unique combinations between agents, such as luspatercept, momelotinib, and pacritinib, particularly in patients with cytopenic myelofibrosis.”

Ruchi J. Desai, MD, an assistant professor in the Division of Hematology, Oncology, and Palliative Care at the Virginia Commonwealth University (VCU) School of Medicine as well as a hematologist/oncologist in the Department of Internal Medicine at VCU Health, discussed notable ongoing studies that are examining agents for the treatment of patinets with myeloproliferative neoplasms.

Desai began by noting that she is anticipating findings from the phase 3 SENTRY trial (NCT04562389), which is evaluating selinexor (Xpovio) in combination with ruxolitinib (Jakafi) for the treatment of patients with myelofibrosis who have not received a JAK inhibitor. The study randomly assigned patients 2:1 to receive selinexor in combination with ruxolitinib or ruxolitinib monotherapy.The coprimary end points are spleen volume response rate of at least 35% at week 24 and the average change in absolute total symptom score over 24 weeks relative to baseline. In September 2025, Karyopharm Therapeutic announced that enrollment to SENTRY was completed and topline data from the study were expected to be shared in March 2026.

Desai noted that she is looking forward to seeing unique combinations containing agents such as luspatercept-aamt (Reblozyl), momelotinib (Ojjaara), and pacritinib (Vonjo) be further evaluated in clinical trials, especially in patient with cytopenic myelofibrosis. Although early, data on the use of interferons for the treatment of patients with myelofibrosis are also of interest, she added.

In the polycythemia vera (PV) space, Desai explained that she is looking forward to seeing data with rusfertide-containing combination regimens. She also hopes to see additional findings with silencing RNA therapies in PV. These agents have the potential to help patients avoid phlebotomy and maintain acceptable hematocrit levels, she concluded.